ArticlePloS one2012
Immunosignaturing can detect products from molecular markers in brain cancer.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Trial
- Immunosignature system for diagnosis of cancer.Proceedings of the National Academy of Sciences of the United States of America · 2014Trial
- Modeling the sequence dependence of differential antibody binding in the immune response to infectious disease.PLoS computational biology · 2023Article
- Reactivity Graph Yields Interpretable IgM Repertoire Signatures as Potential Tumor Biomarkers.International journal of molecular sciences · 2023Article
- Applications of Peptide Microarrays in Autoantibody, Infection, and Cancer Detection.Methods in molecular biology (Clifton, N.J.) · 2023Review
- Article
- High-Throughput Profiling of Circulating Antibody Signatures for Stroke Diagnosis Using Small Volumes of Whole Blood.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2019Article
- Diagnostic Profiling of the Human Public IgM Repertoire With Scalable Mimotope Libraries.Frontiers in immunology · 2019Article
- Liquid biopsy for pediatric central nervous system tumors.NPJ precision oncology · 2018Review
- Immunosignature Differentiation of Non-Infectious Meningoencephalomyelitis and Intracranial Neoplasia in Dogs.Frontiers in veterinary science · 2018Article
- An ImmunoSignature test distinguishes Trypanosoma cruzi, hepatitis B, hepatitis C and West Nile virus seropositivity among asymptomatic blood donors.PLoS neglected tropical diseases · 2017Article
- Synthetic Antibacterial Peptide Exhibits Synergy with Oxacillin against MRSA.ACS medicinal chemistry letters · 2017Article
- Identification of cancer-specific motifs in mimotope profiles of serum antibody repertoire.BMC bioinformatics · 2017Article
- Antibody repertoire profiling with mimotope arrays.Human vaccines & immunotherapeutics · 2017Article
- Adjuvant-Mediated Epitope Specificity and Enhanced Neutralizing Activity of Antibodies Targeting Dengue Virus Envelope Protein.Frontiers in immunology · 2017Article
- High-Resolution Analysis of Antibodies to Post-Translational Modifications Using Peptide Nanosensor Microarrays.ACS nano · 2016Article
- General Assessment of Humoral Activity in Healthy Humans.Molecular & cellular proteomics : MCP · 2016Article
- A General Method to Discover Epitopes from Sera.PloS one · 2016Article
- Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma.Oncoimmunology · 2015Article
- Chimeric peptide constructs comprising linear B-cell epitopes: application to the serodiagnosis of infectious diseases.Scientific reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunosignaturing shows promise as a general approach to diagnosis. It has been shown to detect immunological signs of infection early during the course of disease and to distinguish Alzheimer's disease from healthy controls. Here we test whether immunosignatures correspond to clinical classifications of disease using samples from people with brain tumors. Blood samples from patients undergoing craniotomies for therapeutically naïve brain tumors with diagnoses of astrocytoma (23 samples), Glioblastoma multiforme (22 samples), mixed oligodendroglioma/astrocytoma (16 samples), oligodendroglioma (18 samples), and 34 otherwise healthy controls were tested by immunosignature. Because samples were taken prior to adjuvant therapy, they are unlikely to be perturbed by non-cancer related affects. The immunosignaturing platform distinguished not only brain cancer from controls, but also pathologically important features about the tumor including type, grade, and the presence or absence of O(6)-methyl-guanine-DNA methyltransferase methylation promoter (MGMT), an important biomarker that predicts response to temozolomide in Glioblastoma multiformae patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.